From a drug development perspective, GALE as an enzyme target provides clear structural foundations and mechanisms for designing novel small-molecule drugs, particularly addressing the precision treatment needs for skin barrier dysfunction in atopic dermatitis patients. Here, GALE is linked to atopic eczema.